MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-06-2026
Biogen DSO Ratio 2011-2026 | BIIB
Annual DSO Ratio Biogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.7 | 57.9 | 62.5 | 58.4 | 57.6 | 51.5 | 62.7 | 67.4 | 69 | 55.5 | 52.3 | 59.3 | 56.7 | 63.2 | 58.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69 | 50.7 | 58.9 |
Quarterly DSO Ratio Biogen
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 61.9 | - | 57 | 56.4 | 57.3 | - | 56 | 53.2 | 28.9 | 61.2 | 51.7 | 47.4 | 49 | 46.7 | 47.7 | 47.5 | 50.2 | 50.7 | 52 | 53.2 | 54.6 | 49.3 | 53 | 53 | 52.4 | 45.8 | 44.5 | 45.5 | 44.6 | 39.4 | 40.3 | 43.2 | 45 | 44.7 | 47 | 48.7 | 45.4 | 38.3 | 41.2 | 43.6 | 48.7 | 44.2 | 45.2 | 44.1 | 44.9 | 40.2 | 40.7 | 44.1 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.9 | 28.9 | 47.8 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amarin Corporation plc
AMRN
|
157 | $ 14.81 | -0.34 % | $ 6.04 B |  Irlanda |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Adverum Biotechnologies
ADVM
|
222 | - | - | $ 86.2 M |  USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
53.8 | $ 3.24 | 13.85 % | $ 182 M | China |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.79 | -7.27 % | $ 4.31 M | China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.48 | -0.98 % | $ 8.37 B |  Australia |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 216.28 | -0.83 % | $ 5 B |  Danmark |
 |
Bristol-Myers Squibb Company
BMY
|
83.9 | $ 60.51 | 1.12 % | $ 123 B | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
AgeX Therapeutics
AGE
|
78.4 | - | -10.17 % | $ 12.2 K | USA |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Amneal Pharmaceuticals
AMRX
|
55.7 | $ 14.8 | 1.13 % | $ 4.57 B | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |